In contrast to another previous report (2), we found that LCNEC patients had better survival compared to patients with classic LCC, which might be associated with the enrichment of RB1 and BRAF mutations in the LCNEC group and the enrichment of SMARCA4 and KEAP1 mutations in the LCC group. The gene discussed is BRAF; the disease is large cell neuroendocrine carcinoma.